In the year which marks the 50th anniversary of the publication of The Principles of Humane Experimental Technique by W.M.S. Russell and R.L. Burch, 1 there will undoubtedly be many occasions when the importance of the book will be recognised and the value of their Three Rs concept of Reduction, Refinement and Replacement in relation to animal experimentation will be emphasised. But what truths will really lie behind the grandiose speeches and the receptions at prestigious venues? I have been thinking about this for some time, and I think it would be very interesting to conduct an analysis of what has actually happened since 1959, taking each of the Three Rs in turn.
No comprehensive analysis is needed for the conclusion to be drawn that far too little has been achieved in terms of reduction "in the numbers of animals used to obtain information of a given amount and precision", 1 what Russell and Burch saw "as of great importance, and of all the modes of progress, ...the one most obviously, immediately and universally advantageous in terms of efficiency". 1 Experiments on animals (and, perhaps, experiments in general) continue to be poorly designed and their results inadequately analysed, although there are brave attempts to tackle this problem. The bottom line reveals the truth -the relentless year-by-year increase in the numbers of laboratory animals used in the world continues, fuelled largely by the increasing use of genetically-modified mice. Simil arly, where replacement has occurred, via "the substitution for conscious living higher animals of insentient material", 1 it has overwhelmingly been because of the general progression in biomedical research methodology, rather than because of an explicit desire to avoid the need to cause animal suffering.
It is refinement where the real progress has taken place, the object of which "is simply to reduce, to an absolute minimum, the amount of distress imposed on those animals that are used". 1 This has been achieved as a result of the development of laboratory animal science, together with greater recognition of the importance of specialised veterinarians, technicians, animal carers, and breeders and suppliers, together with the introduction of formal ethical review processes. My suspicion is that this was the intention all along, at least in scientific establishments -to make animal experimentation more respectable and therefore more acceptable, whilst emphasising its importance and praying that replacement for replacement's sake would never catch on.
As has often been said, not least by Russell and Burch themselves, the Three Rs concept seemed to attract little attention for more than 25 years after the publication of The Principles. Then, in the mid-1980s, a number national and international laws which seemed to be based on the concept, were introduced in Europe, that had a great impact on the laws, if not always on the practices, in many European countries: for example, the 
Developments which cause concern
We emerged from the 1990s with the feeling that some progress was being made, albeit in the face of fierce resistance by individuals, organisations and companies committed to defending the continued reliance of biomedical research, testing and education on the use of laboratory animals. However, the beginning of the 21st century has seen various developments which, whilst ostensibly positive and no doubt well-intentioned, have led to confusion, and hence to frustration, among those at all positions across the wide spectrum of views on the extent to which the Three Rs concept could, and should, be actively and forcefully applied, as a means of reducing inhumanity whilst improving the underlying quality of the science, as envisaged by Russell and Burch 50 years ago. Among these developments, in Europe, has been the introduction of the EU REACH system, for the Registration, Evaluation, Authorisation and Restriction Editorial Animal Experimentation and the Three Rs: Time for Honest Answers to Some Leading Questions of Chemicals, 2 and the 7th Amendment to the EU Cosmetics Directive (Directive 76/768/EEC), 3 and the publication of the European Commission's proposals, made after a long period of consultation, for a new Directive to replace Directive 86/609/EEC. 4 As a result, at least as I see it, we have reached a position where the implications of what is going on must be faced, if the gains which have been achieved step-by-step over the last 50 years are not to be lost in a sea of complexity.
Questions to be answered
The main question concerns what impact these developments will have, not only in terms of the Three Rs, but also on science and commerce. However, there are many more-detailed questions, which should be answered honestly and openly by those with the appropriate responsibilities. Here are some of them:
The Principles 1. Russell and Burch said that "progress in replacement has been restricted by certain plausible, but untenable assumptions, which have yielded only gradually and piecemeal to the logic of empirical practice". 1 Why have the scientific, industrial and regulatory communities been so reluctant to face up to the problem of species differences and to heed Russell and Burch's warning about the high-fidelity fallacy?
2. Since, "every time any particle of statistical method is properly used, fewer animals are employed than would otherwise have been necessary", 1 why has so little attention been paid to training in experimental design and the correct use of statistical methods?
3. Do not these first two questions apply particularly forcefully to toxicity testing? Has the situation improved over the last 50 years, since Russell and Burch said, inter alia, "Toxicity testing is, as usual, the scene of some confused thought, which may be delaying the exploitation of statistical methods". 1
Chemicals testing
4. Who will evaluate the benefits of the REACH system, in terms of the greater protection of human health and of the environment, in relation to its costs, to industries, to consumers and to laboratory animals? 5. What agency is responsible for maintaining an account of the additional tests on animals, which will have been conducted in compliance with the REACH system, in terms of their numbers, severities and costs?
6. It has been estimated that about 70% of the animal testing required for compliance with the REACH system will be for reproductive toxicity. What is the evidence that tests on animals can be reliably used to identify chemicals which are likely to be reproductive toxins in humans?
7. The identification of potential human carcinogens is another high-priority issue, but it is questionable whether the rodent bioassay can realistically be expected to identify rodent carcinogens, let alone human carcinogens. What is the evidence that tests on animals can be reliably used to identify chemicals which are likely to be carcinogenic in humans? . If a chemical is tested on animals in compliance with the REACH system, can it be used in cosmetic products to be manufactured and/or marketed within the EU, since it was not tested in animals because the intention was to use it as a cosmetic ingredient?
14. Under what circumstances would a chemical have to be tested on animals for reproductive toxicity or for carcinogenicity, specifically because of its proposed use as a cosmetic ingredient?
15. How can a product, which, it is claimed, "reinforces the skin's natural defence system", "actively prevents skin ageing", "improves skin hydration" and "reduces the degradation of the extra-cellular matrix", as "clearly proved by gene array analysis and in vivo studies", be classed as a cosmetic and not as a pharmaceutical?
16. How will the provisions of the REACH system and of the Cosmetic Directive and its various amendments be applied to nanoparticles?
The proposed new Directive 17. The European Commission's proposals for a new Directive to replace Directive 86/609/ EEC include a provision that would prohibit the use of great apes, with the proviso that Member States could provisionally authorise the use of great apes, where there were "justifiable grounds for believing that action was essential for the preservation of the species or in relation to an unexpected outbreak of a lifethreatening or debilitating clinical condition in human beings, provided that the purpose of the procedure could not be achieved by the use of other species or by the use of alternative methods". The question is: where would the Member States get the great apes from? From zoos? From the wild, and if so, how could research on the preservation of a species be justified, if it involved actions which contributed a threat to the survival of that species?
18. Alternatively, will the European Commission and/or the Member States be encouraged to maintain breeding colonies of great apes, lest such justifiable grounds for using them should arise at some unpredictable time in the future?
19. Many genetically-modified animals appear to be produced at random, in case they might be useful for some unspecified and unknown purpose. Given the vast expansion in the use of genetically-modified animals, should not their production be specifically linked to a scientifically justified and potentially beneficial purpose, before it is permitted? 
Providing a forum
The above 20 questions occurred to me within a few minutes, although, clearly, many of them have been on my mind for some time. I will be seeking answers to them, though I fear that, at least in some cases, those with the relevant responsibilities will not know the answers. When I receive replies, I will see that they are published in ATLA. I would also like to invite other ATLA readers to let me have their questions and their comments, so that we can gain a clearer impression of what is really going on. Some of these questions (and no doubt, many others) have been around since I first became a FRAME Trustee 30 years ago. It's high time that we had some answers… 
